Cleaved-MASP1 (R448) Antibody

What is the specificity of the Cleaved-MASP1 (R448) Antibody?

The Cleaved-MASP1 (R448) Antibody specifically detects endogenous levels of fragment of activated MASP-1 heavy chain (HC) protein resulting from cleavage adjacent to arginine 448 (R448) . This antibody targets the amino acid region 399-448 of human MASP1 and recognizes the activated form that results from autoproteolytic processing . The specificity makes it particularly valuable for studying the activation state of MASP-1 in the complement system, distinguishing between the zymogen and active forms of the protein.

Immunogen information:

• Immunogen Region: 399-448 aa

• The antiserum was produced against synthesized peptide derived from human MASP1

What experimental applications is the Cleaved-MASP1 (R448) Antibody suitable for?

The Cleaved-MASP1 (R448) Antibody has been validated for the following applications:

The antibody is particularly suitable for detecting the activation status of MASP-1 in experimental settings involving complement activation . Western blot analysis has successfully been performed on A549 cells using this antibody, confirming its efficacy in detecting the cleaved form of MASP-1 .

What is the role of MASP-1 in the complement system?

MASP-1 functions in the lectin pathway of complement, which is a critical component of innate immunity. This pathway:

• Is triggered upon binding of mannan-binding lectin (MBL) and ficolins to sugar moieties on pathogen surfaces

• Leads to activation of the associated proteases MASP-1 and MASP-2

• Results in the neutralization of pathogens through complement cascade activation

MASP-1 functions as an endopeptidase and may:

• Activate MASP-2

• Cleave C2 directly

• Directly activate C3, the key component of complement reaction

Additionally, MASP-1 has been found to be essential for the alternative pathway by converting pro-factor D (pro-Df) to its active form, a critical step that was previously thought to occur during secretion .

How are MASP-1 specimens best stored and handled for research applications?

For optimal performance of the Cleaved-MASP1 (R448) Antibody:

• Storage: Store at -20°C for up to 1 year from the date of receipt

• Avoid repeated freeze-thaw cycles

• Formulation: The antibody is provided in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Concentration: Typically supplied at 1 mg/mL

For experimental samples containing MASP-1, it's important to note that MASP-1 circulates in larger complexes (approximately 600 kDa) in calcium-containing buffer and as monomers (approximately 75 kDa) in dissociating buffer .

How can researchers distinguish between MASP-1's direct effects on C3 activation versus its indirect effects through MASP-2 activation?

To differentiate between direct and indirect effects of MASP-1 on complement activation, researchers can employ a strategic experimental approach:

• Use specific inhibitors:

  • SGMI-1: MASP-1-specific inhibitor

  • SGMI-2: MASP-2-specific inhibitor

  These inhibitors allow selective blocking of each pathway to determine contributions .

• Sequential C4 and C3 deposition assays:

  • In a two-step process, first immobilize MBL-MASP complexes on mannan-coated surfaces

  • Add purified C4 to create C4b-saturated plates

  • Subsequently add serum as C2 and C3 source with selective inhibitors

When using this approach, researchers have determined that:

• MASP-1 contributes approximately 60% to C3-convertase formation through C2 cleavage

• MASP-2 contributes approximately 43.5% to the process

• Combined inhibition of both MASP-1 and MASP-2 reduces C3 deposition to background levels (3.3%)

What methodological considerations should be made when investigating MASP-1's role in cleaving pro-factor D to mature factor D?

When investigating MASP-1's role in converting pro-factor D (pro-Df) to mature factor D (Df), several methodological considerations are crucial:

• Experimental models:

  • Use of MASP1/3-deficient mouse models (Masp1/3−/−) reveals that circulating factor D exists as a zymogen (pro-Df) with the activation peptide QPRGR at its N-terminus

  • Human studies comparing normal serum to MASP-1-deficient samples (e.g., from 3MC syndrome patients) can reveal species-specific differences

• Analytical techniques:

  • Mass spectrometric analysis to identify the presence of activation peptides

  • SDS-PAGE and Western blot analysis to detect differences in molecular weight between pro-Df and mature Df

• Functional assays:

  • Alternative pathway activity can be measured through C3 deposition on plates coated with anti-collagen II mAb, as demonstrated in studies with Masp1/3−/− mice

  • Complement activation via alternative pathway should be measured in calcium-deficient buffer with Mg²⁺ and EGTA to prevent classical and lectin pathway activation

• Reconstitution experiments:

  • Addition of recombinant MASP-1 to MASP1/3-deficient serum to restore pro-Df cleavage

  • Addition of recombinant mature factor D to bypass the requirement for MASP-1

These approaches can help elucidate the mechanism by which MASP-1 activates the alternative pathway through pro-Df cleavage, which has been the subject of debate between mouse and human studies .

How can the Cleaved-MASP1 (R448) Antibody be used to investigate the dual role of MASP-1 in complement and coagulation pathways?

MASP-1 exhibits thrombin-like properties and can influence both complement and coagulation systems. To investigate this dual role using the Cleaved-MASP1 (R448) Antibody:

• Clot formation analysis:

  • Perform thrombelastography with MASP-1 alone, thrombin alone, or in combination to assess additive effects

  • The Cleaved-MASP1 (R448) Antibody can be used to detect activated MASP-1 in these contexts

• Substrate specificity studies:

  • MASP-1 has been shown to cleave:

    • Prothrombin (at cleavage site R393, resulting in an alternative active thrombin form)

    • Fibrinogen

    • Factor XIII

    • Protease-activated receptor 4 (PAR4)

• Inhibition studies:

  • Compare inhibition by antithrombin (with heparin) versus C1 inhibitor

  • Research shows antithrombin is a more potent inhibitor of MASP-1 than C1 inhibitor, supporting its thrombin-like properties

• Western blot protocols:

  • Run parallel samples treated with MASP-1, thrombin, or both

  • Use the Cleaved-MASP1 (R448) Antibody to detect the cleaved form

  • Simultaneously probe for coagulation substrates to correlate MASP-1 activation with coagulation effects

This multi-faceted approach can help elucidate how MASP-1 serves as a bridge between innate immunity and coagulation, with potential implications for inflammatory and thrombotic disorders.

What experimental approaches can be used to study MASP-1's activation mechanism in the lectin pathway?

To study MASP-1 activation in the lectin pathway, researchers can employ several experimental approaches:

• C4 deposition assays with different timing scenarios:

  • Direct measurement from human serum (zymogen state): Apply serum to mannan-coated surfaces with or without MASP-1 inhibitor (SGMI-1)

  • Using pre-activated MASPs: First immobilize MBL-MASP complexes on mannan-coated surfaces, then add purified C4 with inhibitors

• Time course experiments:

  • Incubate normal human serum with SGMI-1 on mannan-coated surfaces for extended periods (e.g., two hours at 37°C)

  • Measure C4 deposition at various time points to determine the kinetics of inhibition

• Gel filtration chromatography:

  • To examine if MASP-1 is bound to MBL or other proteins

  • Research has shown that MASP-1 may be present in complexes with proteins other than the traditional MBL-A, MBL-C, or FCN-A, such as FCN-B

• Specific antibody-based detection:

  • Use the Cleaved-MASP1 (R448) Antibody in an inhibition-based assay where antibody binding to MASP-1 domains coated on microtitre wells is inhibited by MASP-1 in the sample

  • This approach has been used to estimate MASP-1 concentrations in donor sera

These approaches reveal that MASP-1 is necessary for MASP-2 activation in the early stages of the lectin pathway, explaining why MASP-1 inhibition completely blocks lectin pathway activity despite MASP-1 not directly cleaving C4 .

What considerations should be made when optimizing Western blot protocols for detecting cleaved MASP-1?

When optimizing Western blot protocols specifically for detecting cleaved MASP-1 using the Cleaved-MASP1 (R448) Antibody, researchers should consider:

• Sample preparation:

  • For serum samples: Dilute in calcium-containing buffer to maintain physiological complexes

  • To observe MASP-1 as a monomer: Use dissociating buffer

  • When using cell lysates (e.g., A549 cells): Ensure complete protease inhibitor cocktail inclusion to prevent artificial activation

• Dilution optimization:

  • Start with the recommended dilution range of 1:500-1:2000 for Western blot

  • Perform titration experiments to determine optimal concentration for specific sample types

• Detection system considerations:

  • Since the antibody is unconjugated, select appropriate secondary antibodies (anti-rabbit IgG)

  • Consider enhanced chemiluminescence systems for optimal sensitivity

• Controls:

  • Positive control: A549 cell lysates have been validated for detecting cleaved MASP-1

  • Negative control: Consider using MASP1-deficient samples or siRNA knockdown cells

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• Gel percentage and transfer conditions:

  • Use 8-10% gels for optimal resolution of the approximately 75 kDa MASP-1 protein

  • Transfer conditions may need optimization based on molecular weight

By carefully optimizing these parameters, researchers can ensure specific and sensitive detection of the cleaved, activated form of MASP-1, distinct from the zymogen form.

How does the study of MASP-1 activation inform our understanding of complement-related inflammatory diseases?

MASP-1 activation plays a significant role in complement-related inflammatory diseases through several mechanisms:

• Alternative pathway regulation:

  • MASP-1's essential role in activating pro-factor D links the lectin and alternative pathways

  • This connection explains why MASP-1 deficiency affects diseases dependent on the alternative pathway

  • Collagen antibody-induced arthritis (CAIA), a model of inflammatory arthritis dependent on the alternative pathway, is markedly inhibited in MASP1/3−/− mice

• Coagulation system cross-talk:

  • MASP-1's thrombin-like activities (cleaving fibrinogen, factor XIII, and PAR4) provide a molecular link between complement activation and coagulation

  • This connection is particularly relevant in inflammatory conditions with concurrent thrombotic manifestations

• C3 convertase formation:

  • MASP-1 generates approximately 60% of C2a responsible for C3 cleavage in the C4b2a enzyme complex

  • This substantial contribution to C3 convertase formation makes MASP-1 a potential therapeutic target for controlling excessive complement activation

Understanding these mechanisms can inform therapeutic strategies targeting MASP-1 for inflammatory diseases where complement dysregulation plays a pathogenic role, potentially offering more selective intervention than broad complement inhibition.

What insights can be gained by comparing results from human samples versus mouse models when studying MASP-1 function?

Comparing human and mouse studies of MASP-1 has revealed important species-specific differences and similarities:

How can researchers quantitatively analyze MASP-1 activation and its contribution to complement pathways?

Quantitative analysis of MASP-1 activation and its contribution to complement pathways can be achieved through several methodological approaches:

• Selective inhibition assays:

  • Using specific inhibitors (SGMI-1 for MASP-1, SGMI-2 for MASP-2) at various concentrations

  • Measuring C3 deposition as a functional readout

  • This approach has quantitatively determined that MASP-1 contributes approximately 60% to C3-convertase formation

• ELISA-based detection methods:

  • Inhibition assay based on anti-MASP-1 antibody binding to MASP-1 domains coated on microtitre wells

  • Donor sera have shown MASP-1 concentrations ranging from 6-12 μg/ml

  • Key protocol elements:

    • Coat wells with MASP-1 domains in carbonate buffer (pH 9.6)

    • Block with HSA at 1 mg/ml TBS

    • Dilute samples in assay buffer (1 M NaCl, 10 mM Tris-HCl, 5 mM CaCl₂, etc.)

    • Mix with rat anti-MASP-1 antiserum (typically 5000-fold dilution)

    • Serum/plasma typically tested at 1.6% final concentration

• Integrated C4/C3 deposition assays:

  • Two-step process to measure C3-convertase formation:

    • First step: Immobilize MBL-MASP complexes and add purified C4 to create C4b-saturated plates

    • Second step: Add serum as C2 and C3 source with selective inhibitors

  • This approach can quantify the contribution of MASP-1 to generating the C2a component of C3-convertase

• Western blot with densitometry:

  • Using the Cleaved-MASP1 (R448) Antibody to detect the activated form

  • Quantifying band intensity relative to total MASP-1 to determine activation percentage

  • Recommended dilution range: 1:500-1:2000